Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
about
The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cellsAlternative polyadenylation of cyclooxygenase-2.Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significanceThe dual role of tumor lymphatic vessels in dissemination of metastases and immune response developmentCyclooxygenase in the treatment of glioma: its complex role in signal transductionInflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancerCyclooxygenase-2 and the inflammogenesis of breast cancer.Prostaglandins regulate nuclear localization of Fascin and its function in nucleolar architecture.Association of 15-hydroxyprostaglandin dehydrogenate and poor prognosis of obese breast cancer patients.Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.The influence of Cox-2 and bioactive lipids on hematological cancers.Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patientsAspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial.Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.Cyclooxygenase- and lipoxygenase-mediated DNA damage.Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancerOpposing roles for mammary epithelial-specific PPARĪ³ signaling and activation during breast tumour progressionOverexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neuCOX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirinRecent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort studyExpression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphomaMacrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors.Drosophila Fascin is a novel downstream target of prostaglandin signaling during actin remodeling.COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.COX-2 modulates mammary tumor progression in response to collagen density.TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cellsCombination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoidAntitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression.Impact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients.Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkersCOX-2 expression correlates with survival in patients with osteosarcoma lung metastases.Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapyRole of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer.Physiological COX-2 expression in breast epithelium associates with COX-2 levels in ductal carcinoma in situ and invasive breast cancer in young womenClinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Cyclooxygenase-2 expression in animal cancers.
P2860
Q24305557-A5448EEF-AC16-478D-BF19-F6E8E34CF267Q24798039-982AD71D-C985-4F6A-8ADB-E30A65955857Q24813854-A352BE0F-EBF9-4ED5-AF88-232BC3CA9BDFQ28076945-0730E1C3-B6A5-42A7-A35A-4D6F55A3DFC4Q28168685-27E76A52-3C4C-4716-B251-BDB1164922A5Q28218639-E83794E0-038D-491D-AEB6-8E088FF0A709Q30367680-98F1DDF9-A439-4240-90F1-69DDAD68A11AQ30651049-CE1F999A-7666-4B3B-A464-E7C7B2D572E3Q33618485-C872EC81-250E-44DA-AED4-073532C51B94Q33659189-1B6A2B20-1CF1-46A9-8EAD-52E2563AE99AQ33688673-29C112C1-AD28-4864-ACEA-1068768E4D77Q33932996-D2FDEEA9-6323-43B1-AC93-F1DA5FE6970BQ34135505-78067721-F256-4B19-9CEC-08F00C5870CBQ34206453-D50EDEB6-D67B-446B-B74D-F8C8B24FE03CQ34225293-6BA78CE7-6DBA-4255-9AB9-62E68CB390C3Q34996098-EDCB2B5D-2970-42EC-8554-36D04D40CD97Q35108403-FCE7C688-B61D-4C8B-A376-69EC8FDA2FFEQ35576310-4E4A8373-E074-488E-8D2E-89EA2772A39EQ35770111-544FC2EF-56B9-44C6-A582-91F198974F7DQ35797114-863E826E-4F5D-49C4-AAAB-89AEDA4169C3Q35911030-9285D9C5-B8CC-46D7-9A4A-DD1AF0BB2A43Q36065849-4DA37147-1FA2-4FEC-8799-18A683EDA284Q36198192-EE018AFF-42EE-44E4-A96C-6026D8AED9DCQ36433783-4C9C97E0-4427-4E52-A931-4CBCA983E44FQ36694470-C269ED09-A7CD-4C67-BDA9-303713DBC181Q36715145-AD4DCA9E-4C7E-4C03-A16B-0C60B5C571C1Q36787339-1286C505-0D59-47EB-B6F4-90AE937516E2Q37033840-BB1B163D-C7DC-4B94-AA44-7D8DA7ACAD0BQ37052186-2D6FFB4B-FB42-486A-9499-52976D1C9EE5Q37083917-C8EB7F4F-0063-4AE8-A546-036DFBFF2907Q37088155-C635C17A-7AB8-4C8B-B003-4A2D568A6205Q37326197-A600F527-B5E9-4E77-BE23-1584468CFF69Q37408537-87DC7FE4-CF14-43B1-B379-653CC8272ABBQ37467199-4EFA0F97-6337-4773-A10B-E6EAB0A0C186Q37660357-50764FE0-2B81-4902-86D5-A108BED36A5CQ37672896-B4B35B35-A836-4EDD-877F-C0E83FFA7A8BQ37701526-7A76D719-302C-4B75-B54C-B9C63087930AQ37701635-F28AB02E-5112-47E7-A91D-09EB80F4C3C5Q37709099-D87901DA-56AC-46BD-ADC7-2B6C0D644274Q37793667-158A2EA8-F35C-4787-B729-280F77ECAF5A
P2860
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
description
2003 nĆ® lÅ«n-bĆ»n
@nan
2003幓ć®č«ę
@ja
2003幓å¦ęÆęē«
@wuu
2003幓å¦ęÆęē«
@zh-cn
2003幓å¦ęÆęē«
@zh-hans
2003幓å¦ęÆęē«
@zh-my
2003幓å¦ęÆęē«
@zh-sg
2003幓åøč”ęē«
@yue
2003幓åøč”ęē«
@zh
2003幓åøč”ęē«
@zh-hant
name
Elevated expression of cycloox ...... atients with breast carcinoma.
@en
Elevated expression of cycloox ...... atients with breast carcinoma.
@nl
type
label
Elevated expression of cycloox ...... atients with breast carcinoma.
@en
Elevated expression of cycloox ...... atients with breast carcinoma.
@nl
prefLabel
Elevated expression of cycloox ...... atients with breast carcinoma.
@en
Elevated expression of cycloox ...... atients with breast carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Elevated expression of cycloox ...... atients with breast carcinoma.
@en
P2093
Angela Reles
Antje Siegert
Berit-Maria MĆ¼ller
Glen Kristiansen
Hans Guski
Klaus-JĆ¼rgen Winzer
Steffen Hauptmann
Sƶren Pest
Wilko Weichert
P2860
P304
P356
10.1002/CNCR.11437
P407
P577
2003-06-01T00:00:00Z